You are here

Troponin Test May Help Doctors Diagnose Heart Attacks in Women

Researchers study new protein assay in 25,000 subjects (September 4)

Promising preliminary results have been reported from a study presented at the European Society of Cardiology Congress 2013, suggesting that a highly sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack. The test could be particularly beneficial for women, who may have different presenting symptoms and are often under-diagnosed.

The study, which is being conducted by researchers in Scotland, is evaluating the Architect Stat High Sensitive Troponin-I (hsTnI) test (Abbott).

Cardiac troponin — a protein found in the heart muscle — is the preferred biomarker to identify suspected heart attacks because it can detect injury to the heart. The hsTnI test can measure very low levels of this protein, which is especially important for women, who often have lower levels of troponin than men.

Researchers presented data from the first 1,126 patients in the study. When completed in 2016, the investigation will include more than 25,000 patients, making it one of the largest studies to evaluate the effect of highly sensitive troponin tests on patient care.

The Architect Stat hsTnI assay is commercially available in several countries in Europe, as well as in Canada, Australia, New Zealand, and Brazil. Currently, the test is only for research use in the U.S.

Source: Abbott; September 4, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress